

## Brilliant Violet 605™ anti-mouse/human CD11b Antibody

<b>Catalog# / Size</b>	101237 / 125 µL 101257 / 50 µg
<b>Clone</b>	M1/70
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

### Product Details

<b>Verified Reactivity</b>	Mouse, Human, Cynomolgus, Rhesus
<b>Reported Reactivity</b>	Chimpanzee, Baboon, Rabbit
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	C57BL/10 splenocytes
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.  Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.  <a href="#">Learn more about Brilliant Violet™.</a>
<b>Excitation Laser</b>	Violet Laser (405 nm)

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

## Application Notes

Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation<sup>1,4</sup>, *in vitro* blocking<sup>3,9,12</sup>, depletion<sup>2,8</sup>, immunofluorescence microscopy<sup>6,7,10</sup>, immunohistochemistry of acetone-fixed frozen sections<sup>5,11-13</sup>, and spatial biology (IBEX)<sup>35,36</sup>. For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) (Cat. No. 101248).

## Application References

(PubMed link indicates BioLegend citation)

1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, *et al.* 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Gallizioli M, *et al.* 2020. *Cell Rep.* 33:108291. [PubMed](#)
2. Michela Miani *et al.* 2018. *Cell metabolism.* 28(4):557-572. [PubMed](#)
3. Tran NT, *et al.* 2019. *Cell Rep.* 28:3510. [PubMed](#)
4. Komuczki J, *et al.* 2019. *Immunity.* 50:1289. [PubMed](#)
5. Saha D *et al.* 2017. *Cancer cell.* 32(2):253-267. [PubMed](#)
6. Iwahori K, *et al.* 2019. *Sci Rep.* 2.205555556. [PubMed](#)
7. Garber C, *et al.* 2019. *Nat Neurosci.* 1.802777778. [PubMed](#)
8. Marchelletta RR, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
9. Rosenheinrich M, *et al.* 2015. *PLoS One.* 10: 0136290. [PubMed](#)
10. Herz J, *et al.* 2015. *J Exp Med.* 212: 1153 - 1169. [PubMed](#)
11. Ferrere G, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
12. Jong RM, *et al.* 2022. *J Immunol.* 208:407. [PubMed](#)
13. Boal-Carvalho I, *et al.* 2020. *EMBO Rep.* 21:e50421. [PubMed](#)
14. Ma J, *et al.* 2020. *Adv Sci (Weinh).* 7:2000609. [PubMed](#)
15. Morris MG, *et al.* 2020. *Comp Med.* 70:336. [PubMed](#)
16. Merz SF, *et al.* 2019. *Nat Commun.* 10:2312. [PubMed](#)
17. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
18. Karlen SJ, *et al.* 2018. *J Neuroinflammation.* 15:344. [PubMed](#)
19. Frank AC, *et al.* 2021. *Theranostics.* 11:7570. [PubMed](#)
20. Rodriguez-García A, *et al.* 2021. *Nat Commun.* 12:877. [PubMed](#)
21. Song J, *et al.* 2021. *J Am Heart Assoc.* 10:e017329. [PubMed](#)
22. Pan Y, *et al.* 2021. *Front Cell Neurosci.* 15:664312. [PubMed](#)
23. Hu J, *et al.* 2021. *Sci Adv.* 7:. [PubMed](#)
24. Hu W, *et al.* 2021. *Nat Immunol.* 22:1163. [PubMed](#)
25. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
26. Bauer KM, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
27. Piper CJM, *et al.* 2020. *Cell Reports.* 29(7):1878-1892.e7.. [PubMed](#)
28. Schmidleithner L *et al.* 2019. *Immunity.* 50(5):1232-1248. [PubMed](#)
29. Tordesillas L, *et al.* 2018. *Nat Commun.* 9:5238. [PubMed](#)
30. Bratti M, *et al.* 2022. *Front Immunol.* 13:1029759. [PubMed](#)
31. Huard A, *et al.* 2021. *J Immunol.* 206:1058. [PubMed](#)

32. Chen WS, *et al.* 2021. Cell Rep. 37:109974. [PubMed](#)
33. Si Y, *et al.* 2020. Sci Adv. 6:eaba0995. [PubMed](#)
34. Zhao B, *et al.* 2021. Cell Reports. 36(3):109401. [PubMed](#)
35. Webster HC, *et al.* 2020. J Immunol Methods. 112702:477. [PubMed](#)
36. Macpherson L, *et al.* 2020. Nature. 577:266. [PubMed](#)
37. Han Y *et al.* 2019. Cell reports. 27(3):835-846 . [PubMed](#)
38. Christopher S Garris *et al.* 2018. Immunity. 49(6):1148-1161 . [PubMed](#)
39. Chan YH, *et al.* 2019. EMBO Mol Med. 11:e10092. [PubMed](#)
40. Gómez-Díaz C, *et al.* 2021. iScience. 24:103241. [PubMed](#)
41. Ostendorf BN, *et al.* 2020. Nat Med. 26:1048. [PubMed](#)
42. Dieterich LC, *et al.* 2019. International Journal of Cancer. 145(10):2804-2815. [PubMed](#)
43. Wang C, *et al.* 2021. Cell Stem Cell. . [PubMed](#)
44. Cousin N, *et al.* 2021. Cancer Res. 81:4133. [PubMed](#)
45. Niss K, *et al.* 2020. Cell Reports. 31(11):107763. [PubMed](#)
46. Ruhland MK, *et al.* 2020. Cancer Cell. 37(6):786-799.e5. [PubMed](#)
47. Iannello A, *et al.* 2013. J Exp Med. 210:2057. [PubMed](#)
48. Ray A, *et al.* 2015. PLoS One. 10: 0137314. [PubMed](#)
49. Linehan JL *et al.* 2018. Cell. 172(4):784-796 . [PubMed](#)
50. Bonnardel J, *et al.* 2019. Immunity. 51:638. [PubMed](#)
51. Dar HH, *et al.* 2022. JCI Insight. 7:. [PubMed](#)
52. Li Y, *et al.* 2022. J Neuroinflammation. 19:261. [PubMed](#)
53. Tacconi C, *et al.* 2021. Cell Reports. 35(2):108993. [PubMed](#)
54. Ringel AE, *et al.* 2020. Cell. 183(7):1848-1866.e26. [PubMed](#)
55. McBride KM, *et al.* 2019. Front Oncol. 9:517. [PubMed](#)
56. Tavazoie MF, *et al.* 2018. Cell. 172:825. [PubMed](#)
57. Sheng W *et al.* 2018. Cell. 174(3):549-563 . [PubMed](#)
58. Campbell C *et al.* 2018. Immunity. 48(6):1245-1257 . [PubMed](#)
59. Stotesbury C, *et al.* 2020. J Immunol. 204:1582. [PubMed](#)
60. Deerhake ME, *et al.* 2021. Immunity. 54(3):484-498.e8. [PubMed](#)
61. Martínez-López M *et al.* 2019. Immunity. 50(2):446-461 . [PubMed](#)
62. Yang H, *et al.* 2019. J Neuroinflammation. 16:169. [PubMed](#)
63. Sun T, *et al.* 2017. Mucosal Immunol. 0.954861111. [PubMed](#)
64. Branchett WJ, *et al.* 2020. Wellcome Open Research. 0.278472222. [PubMed](#)
65. Yang C, *et al.* 2022. Research (Wash D C). 2022:9768687. [PubMed](#)
66. Aktories P, *et al.* 2022. Cell Rep Methods. 2:100260. [PubMed](#)
67. Cohen M *et al.* 2018. Cell. 175(4):1031-1044 . [PubMed](#)
68. Wang YT, *et al.* 2020. Nat Microbiol. 0.397222222. [PubMed](#)
69. Alam Z, *et al.* 2020. Cell Rep. 107825:31. [PubMed](#)
70. Yang BH, *et al.* 2020. Cell Reports. 27(12):3629-3645.e6.. [PubMed](#)
71. Dudeck J, *et al.* 2019. J Allergy Clin Immunol. 143:1849. [PubMed](#)
72. Zeng Q, *et al.* 2022. iScience. 25:105151. [PubMed](#)
73. Hamaidi I, *et al.* 2020. Cell Metabolism. 32(3):420-436.e12. [PubMed](#)
74. Mansouri S, *et al.* 2020. Mucosal Immunol. 0.954861111. [PubMed](#)
75. Goh W, *et al.* 2020. Cell Rep. 33:108285. [PubMed](#)
76. Swanson P, *et al.* 2016. PLoS Pathog. 12:e1006022. [PubMed](#)
77. Godwin MS, *et al.* 2019. JCI Insight. 4:e126070. [PubMed](#)
78. Pinho-Ribeiro FA, *et al.* 2018. Cell. 173:1083. [PubMed](#)
79. Rive CM, *et al.* 2022. Mol Ther Methods Clin Dev. 26:4. [PubMed](#)
80. Shi H, *et al.* 2015. Nat Immunol. . [PubMed](#)
81. Macal M *et al.* 2018. Immunity. 48(4):730-744 . [PubMed](#)
82. Urata S, *et al.* 2018. PLoS Pathog. 14:e1007172. [PubMed](#)
83. Yousef H, *et al.* 2019. Nat Med. 25:988. [PubMed](#)
84. Rosser EC, *et al.* 2020. Cell Metabolism. 31(4):837-851. [PubMed](#)
85. Luo M, *et al.* 2021. J Immunol. 207:1683. [PubMed](#)
86. Montalban-Arques A, *et al.* 2021. Cell Host Microbe. . [PubMed](#)
87. Xu C, *et al.* 2020. Immunity. 53(2):417-428.e4. [PubMed](#)
88. Zhu YP *et al.* 2018. Cell reports. 24(9):2329-2341 . [PubMed](#)
89. Li N, *et al.* 2022. Nat Commun. 13:7281. [PubMed](#)
90. Nam J, *et al.* 2021. Adv Ther (Weinh). 4:. [PubMed](#)
91. Leary N, *et al.* 2022. J Extracell Vesicles. 11:e12197. [PubMed](#)
92. Crichton M, *et al.* 2016. Sci Rep. 6:27217. [PubMed](#)
93. Frank AC, *et al.* 2019. Nat Commun. 10:1135. [PubMed](#)
94. Bommareddy PK, *et al.* 2019. J Biol Methods. 6:2. [PubMed](#)
95. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. [PubMed](#)
96. Melhem NJ, *et al.* 2021. Circulation. 143:566. [PubMed](#)
97. Mujal AM, *et al.* 2022. Cancer Immunol Res. 10:403. [PubMed](#)
98. Srivastava S, *et al.* 2020. Cancer Cell. 39(2):193-208.e10. [PubMed](#)
99. White JP *et al.* 2018. Cell. 175(5):1198-1212 . [PubMed](#)
100. Seenappa LM, *et al.* 2022. NPJ Vaccines. 7:128. [PubMed](#)
101. Rosen SF, *et al.* 2022. Genome Med. 14:108. [PubMed](#)
102. Stotesbury C, *et al.* 2020. Aging Cell. 19:e13170. [PubMed](#)
103. Wang T, *et al.* 2015. Proc Natl Acad Sci U S A. 112:440. [PubMed](#)
104. O'Boyle C, *et al.* 2020. Int J Stroke. 0.746527778. [PubMed](#)
105. Lai NY, *et al.* 2020. Cell. 180:33:00. [PubMed](#)
106. Kastenschmidt JM, *et al.* 2021. Cell Rep. 35:108997. [PubMed](#)
107. Rivera CA, *et al.* 2022. Immunity. 55:129. [PubMed](#)
108. C Khouili S, *et al.* 2020. Cell Rep. 33:108468. [PubMed](#)
109. Sparber F *et al.* 2019. British journal of pharmacology. 176(11):1728-1744 . [PubMed](#)
110. Bretou M, *et al.* 2017. Sci Immunol. 2:16. [PubMed](#)
111. Fearon AE, *et al.* 2021. iScience. 24:103143. [PubMed](#)

112. Liu Y, *et al.* 2021. Nat Commun. 12:6831. [PubMed](#)  
 113. Li X, *et al.* 2021. Front Immunol. 12:779560. [PubMed](#)  
 114. Matei DE, *et al.* 2021. Med (N Y). 2:864. [PubMed](#)

**RRID** AB\_11126744 (BioLegend Cat. No. 101237)  
 AB\_2565431 (BioLegend Cat. No. 101257)

## Antigen Details

<b>Structure</b>	Integrin family, associates with integrin $\beta_2$ (CD18), 170 kD
<b>Distribution</b>	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
<b>Function</b>	Adhesion, chemotaxis
<b>Ligand/Receptor</b>	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
<b>Cell Type</b>	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
<b>Molecular Family</b>	Adhesion Molecules, CD Molecules
<b>Antigen References</b>	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Coxon A, <i>et al.</i> 1996. <i>Immunity</i> 5:653.
<b>Gene ID</b>	<a href="#">16409</a> <a href="#">3684</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

## Product Data



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 605™. Data shown was gated on myeloid cell population.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587